Referências
Principais artigos
Amescua G, Akpek EK, Farid M, et al. Blepharitis Preferred Practice Pattern®. Ophthalmology. 2019 Jan;126(1):P56-P93.Texto completo Resumo
The College of Optometrists. Clinical management guidelines: Blepharitis (lid margin disease). 2022 [internet publication]. Texto completo
American Academy of Ophthalmology. Cornea/external disease summary benchmarks - 2022. 2022 [internet publication]. Texto completo
Artigos de referência
1. Amescua G, Akpek EK, Farid M, et al. Blepharitis Preferred Practice Pattern®. Ophthalmology. 2019 Jan;126(1):P56-P93.Texto completo Resumo
2. The College of Optometrists. Clinical management guidelines: Blepharitis (lid margin disease). 2022 [internet publication]. Texto completo
3. McCulley JP, Sciallis GF. Meibomian keratoconjunctivitis. Am J Ophthalmol. 1977 Dec;84(6):788-93. Resumo
4. Stone DU, Chodosh J. Ocular rosacea: an update on pathogenesis and therapy. Curr Opin Ophthalmol. 2004 Dec;15(6):499-502. Resumo
5. Driver PJ, Lemp MA. Meibomian gland dysfunction. Surv Ophthalmol. 1996 Mar-Apr;40(5):343-67. Resumo
6. Lemp MA, Nichols KK. Blepharitis in the United States 2009: a survey-based perspective on prevalence and treatment. Ocul Surf. 2009 Apr;7(2 suppl):S1-S14.Texto completo Resumo
7. Lemp MA, Crews LA, Bron AJ, et al. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012 May;31(5):472-8. Resumo
8. Rim TH, Kang MJ, Choi M, et al. Ten-year incidence and prevalence of clinically diagnosed blepharitis in South Korea: a nationwide population-based cohort study. Clin Exp Ophthalmol. 2017 Jul;45(5):448-454.Texto completo Resumo
9. Boel C, Westerveld E, Kloos D, et al. Refining the diagnostic technique to determine prevalence of Demodex mites in eyelash hair follicles within standard ophthalmic practice: a single-center outpatient clinical study. Clin Ophthalmol. 2023;17:2027-36.Texto completo Resumo
10. Trattler W, Karpecki P, Rapoport Y, et al. The prevalence of Demodex blepharitis in US eye care clinic patients as determined by collarettes: a pathognomonic sign. Clin Ophthalmol. 2022;16:1153-64.Texto completo Resumo
11. Dougherty JM, McCulley JP. Comparative bacteriology of chronic blepharitis. Br J Ophthalmol. 1984 Aug;68(8):524-8.Texto completo Resumo
12. Groden LR, Murphy B, Rodnite J, et al. Lid flora in blepharitis. Cornea. 1991 Jan;10(1):50-3. Resumo
13. Thygeson P. Etiology and treatment of blepharitis. Arch Ophthalmol. 1946 Oct;36(4):445-77.
14. Schaumberg DA, Nichols JJ, Papas EB, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD. Invest Ophthalmol Vis Sci. 2011 Mar;52(4):1994-2005.Texto completo Resumo
15. Luo X, Li J, Chen C, et al. Ocular demodicosis as a potential cause of ocular surface inflammation. Cornea. 2017 Nov;36 Suppl 1(suppl 1):S9-14. Resumo
16. Liu J, Sheha H, Tseng SC. Pathogenic role of Demodex mites in blepharitis. Curr Opin Allergy Clin Immunol. 2010 Oct;10(5):505-10. Resumo
17. Zeytun E, Karakurt Y. Prevalence and load of Demodex folliculorum and Demodex brevis (Acari: Demodicidae) in patients with chronic blepharitis in the Province of Erzincan, Turkey. J Med Entomol. 2019 Jan 8;56(1):2-9.Texto completo Resumo
18. Dougherty JM, McCulley JP. Bacterial lipases and chronic blepharitis. Invest Ophthalmol Vis Sci. 1986;27:486-491.Texto completo Resumo
19. Shine WE, Silvany R, McCulley JP. Relation of cholesterol-stimulated Staphylococcus aureus growth to chronic blepharitis. Invest Ophthalmol Vis Sci. 1993 Jun;34(7):2291-6.Texto completo Resumo
20. Ficker L, Ramakrishnan M, Seal D, et al. Role of cell-mediated immunity to staphylococci in blepharitis. Am J Ophthalmol. 1991 Apr 15;111(4):473-9. Resumo
21. Amano S, Shimazaki J, Yokoi N, et al. Meibomian gland dysfunction Clinical Practice Guidelines. Jpn J Ophthalmol. 2023 Jul;67(4):448-539.Texto completo Resumo
22. Mathers WD, Shields WJ, Sachdev MS, et al. Meibomian gland dysfunction in chronic blepharitis. Cornea. 1991 Jul;10(4):277-85. Resumo
23. Jester JV, Nicolaides N, Smith RE. Meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 1989 May;30(5):927-35.Texto completo Resumo
24. Dougherty JM, McCulley JP. Analysis of the free fatty acid component of meibomian secretions in chronic blepharitis. Invest Ophthalmol Vis Sci. 1986 Jan;27(1):52-6.Texto completo Resumo
25. Shine WE, McCulley JP. The role of cholesterol in chronic blepharitis. Invest Ophthalmol Vis Sci. 1991 Jul;32(8):2272-80.Texto completo Resumo
26. Shine WE, McCulley JP. Meibomianitis: polar lipid abnormalities. Cornea. 2004 Nov;23(8):781-3. Resumo
27. Shah PP, Stein RL, Perry HD. Update on the management of Demodex blepharitis. Cornea. 2022 Aug 1;41(8):934-9. Resumo
28. IMS America. National disease and therapeutic index. Ambler, PA: IMS America, Ltd., 1984.
29. Akpek EK, Polcharoen W, Chan R, et al. Ocular surface neoplasia masquerading as chronic blepharoconjunctivitis. Cornea. 1999 May;18(3):282-8. Resumo
30. Brownstein B, Codere F, Jackson WB. Masquerade syndrome. Ophthalmology. 1980 Mar;87(3):259-62.
31. Gao YY, Di Pascuale M, Li W, et al. High prevalence of Demodex in eyelashes with cylindrical dandruff. Invest Ophthalmol Vis Sci. 2005 Sep;46(9):3089-94.Texto completo Resumo
32. Ayres BD, Donnenfeld E, Farid M, et al. Clinical diagnosis and management of Demodex blepharitis: the Demodex Expert Panel on Treatment and Eyelid Health (DEPTH). Eye (Lond). 2023 Oct;37(15):3249-55.Texto completo Resumo
33. Key JE. A comparative study of eyelid cleaning regimens in chronic blepharitis. CLAO J. 1996 Jul;22(3):209-12. Resumo
34. Macsai MS. The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis). Trans Am Ophthalmol Soc. 2008;106:336-56.Texto completo Resumo
35. Dry Eye Assessment and Management Study Research Group., Asbell PA, Maguire MG, et al. n-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease. N Engl J Med. 2018 May 3;378(18):1681-1690.Texto completo Resumo
36. Bowman RW, Dougherty JM, McCulley JP. Chronic blepharitis and dry eyes. Int Ophthalmol Clin. 1987 Spring;27(1):27-35. Resumo
37. Perry HD, Doshi-Carnevale S, Donnenfeld ED, et al. Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea. 2006 Feb;25(2):171-5. Resumo
38. Lindsley K, Matsumura S, Hatef E, Akpek EK. Interventions for chronic blepharitis. Cochrane Database Syst Rev. 2012 May 16;(5):CD005556.Texto completo Resumo
39. O'Gallagher M, Bunce C, Hingorani M et al. Topical treatment for blepharokeratoconjunctivitis (BKC) in children. Cochrane Database Syst Rev. 2017 Feb 7;2:CD011965.Texto completo
40. Smolin G, Okumoto M. Staphylococcal blepharitis. Arch Ophthalmol. 1977 May;95(5):812-6. Resumo
41. Tao T, Tao L. Systematic review and meta-analysis of treating meibomian gland dysfunction with azithromycin. Eye (Lond). 2020 Oct;34(10):1797-808.Texto completo Resumo
42. Dursun K, Kim MC, Solomon A, et al. Treatment of recalcitrant recurrent corneal erosions with inhibitors of matrix metalloproteinase-9, doxycycline, and corticosteroids. Am J Ophthalmol. 2001 Jul;132(1):8-13. Resumo
43. Farid M, Ayres BD, Donnenfeld E, et al. Delphi panel consensus regarding current clinical practice management options for Demodex blepharitis. Clin Ophthalmol. 2023;17:667-79.Texto completo Resumo
44. Savla K, Le JT, Pucker AD. Tea tree oil for Demodex blepharitis. Cochrane Database Syst Rev. 2020 Jun 20;6:CD013333.Texto completo Resumo
45. Lam NSK, Long XX, Li X, et al. Comparison of the efficacy of tea tree (Melaleuca alternifolia) oil with other current pharmacological management in human demodicosis: a systematic review. Parasitology. 2020 Dec;147(14):1587-613.Texto completo Resumo
46. BioSpace. FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis. 2023 [internet publication].Texto completo
47. Yeu E, Wirta DL, Karpecki P, et al. Lotilaner ophthalmic solution, 0.25%, for the treatment of Demodex blepharitis: results of a prospective, randomized, vehicle-controlled, double-masked, pivotal trial (Saturn-1). Cornea. 2023 Apr 1;42(4):435-43.Texto completo Resumo
48. Gaddie IB, Donnenfeld ED, Karpecki P, et al. Lotilaner ophthalmic solution 0.25% for Demodex blepharitis: randomized, vehicle-controlled, multicenter, phase 3 trial (Saturn-2). Ophthalmology. 2023 Oct;130(10):1015-23.Texto completo Resumo
49. Yeu E, Holdbrook M, Baba SN, et al. Treatment of Demodex blepharitis: a prospective, randomized, controlled, double-masked clinical trial comparing topical lotilaner ophthalmic solution, 0.25% eyedrops to vehicle. Ocul Immunol Inflamm. 2023 Oct;31(8):1653-61.Texto completo Resumo
50. American Academy of Ophthalmology. Cornea/external disease summary benchmarks - 2022. 2022 [internet publication]. Texto completo
51. Dougherty JM, McCulley JP, Silvany RE, et al. The role of tetracycline in chronic blepharitis. Inhibition of lipase production in staphylococci. Invest Ophthalmol Vis Sci. 1991 Oct;32(11):2970-5.Texto completo Resumo
52. Cullen SI, Crounse RG. Cutaneous pharmacology of the tetracyclines. J Invest Derm. 1965 Oct;45(4):263-8. Resumo
53. Zengin N, Tol H, Gunduz K, et al. Meibomian gland dysfunction and tear film abnormalities in rosacea. Cornea. 1995 Mar;14(2):144-6. Resumo
54. Ta CN, Shine WE, McCulley JP, et al. Effects of minocycline on the ocular flora of patients with acne rosacea or seborrheic blepharitis. Cornea. 2003 Aug;22(6):545-8. Resumo
55. Shine WE, McCulley JP, Pandya AG. Minocycline effect on meibomian gland lipids in meibomianitis patients. Exp Eye Res. 2003;76;417-420. Resumo
56. Onghanseng N, Ng SM, Halim MS, et al. Oral antibiotics for chronic blepharitis. Cochrane Database Syst Rev. 2021 Jun 9;6(6):CD013697.Texto completo Resumo
57. Gruber GC, Callen JP. Systemic complications of commonly used dermatologic drugs. Cutis. 1978 Jun;21(6):825-9. Resumo
58. American Academy of Ophthalmology. Referral of persons with possible eye diseases or injury - 2014. 2014 [internet publication].Texto completo
O uso deste conteúdo está sujeito ao nosso aviso legal